Telmisartan, ramipril, or both in high-risk Chinese patients: Analysis of ONTARGET China data

Chinese Medical Journal

Volumn 124, Issue 12, 2011, Pages 1763-1768

  Yu, Li tian ^a   Zhu, Jun ^a   Tan, Hui qiong ^a   Wang, Guo gan ^a   Teo, Koon K ^b   Liu, Li sheng ^a  

^a FUWAI HOSPITAL   (China)

^b HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

High risk; Ramipril; Telmisartan

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; RAMIPRIL; TELMISARTAN;

ADULT; AGED; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ARTICLE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHINESE; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIALYSIS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INCIDENCE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; PATIENT COMPLIANCE; REVASCULARIZATION; SIDE EFFECT; SMOKING; STROKE; SYNCOPE; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; CHINA; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; RAMIPRIL;

EID: 79959497070     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.12.001     Document Type: Article

References (19)

1. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
2. Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/ TRANSCEND) trials. Am Heart J 2004; 148: 52-61.
3. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.
4. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
5. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368: 581-588.
6. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-776.
7. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
8. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-771.
9. Su DF. Prevention and treatment strategies for stroke from basic research. Chin J Geriatr Heart Brain Vess Dis (Chin) 2008; 10: 86.
10. Rao ML. Chinese guideline for prevention and treatment of cerebrovascular disease. Beijing: People's Medical Publishing House; 2007: 1.
11. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
12. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) Study. Circulation 1999; 99: 216-223.
13. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
14. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006; 47: 2130-2139.
15. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention. Eur Heart J 2007: 28: 2375-2414.
16. Dhamoon MS, Sciacca RR, Rundek T, Sacco RL, Elkind MS. Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study. Neurology 2006; 66: 641-646.
17. Feng W, Hendry RM, Adams RJ. Risk of recurrent stroke, myocardial infarction, or death in hospitalized stroke patients. Neurology 2010; 74: 588-593.
18. Azarpazhooh MR, Nicol MB, Donnan GA, Dewey HM, Sturm JW, Macdonell RA, et al. Patterns of stroke recurrence according to subtype of first stroke event: the North East Melbourne Stroke Incidence Study (NEMESIS). Int J Stroke 2008; 3: 158-164.
19. Xu G, Liu X, Wu W, Zhang R, Yin Q. Recurrence after ischemic stroke in Chinese patients: impact of uncontrolled modifiable factors. Cerebrovasc Dis 2007; 23: 117-120.